Kedrion Biopharma an important Share Purchase Agreement with Liminal BioSciences Inc. The agreement is for the purchase of Prometic Bioproduction Inc, a production plant in Québec (the "First Closing"), and Prometic Biotherapeutics Inc, which holds the biological license application for an FDA-approved drug to treat Plasminogen Deficiency type 1 (Hypoplasminogenemia), a rare systemic disease (the "Second Closing"). Crédit Agricole Corporate and Investment Bank, Intesa Sanpaolo S.p.A., Mediobanca - Banca di Credito Finanziario S.p.A., Natixis and UniCredit Bank AG served as joint bookrunners.